Alliance for Safe Biologic Medicines Launches Webinar Series

Alliance for Safe Biologic Medicines Launches Webinar Series

Starting in November, The Alliance for Safe Biologic Medicines will host several webinars on biologic and biosimilar medicines, hosted by Alliance Chairman Dr. Richard Dolinar. Registration is free!

Biologics 101: What are biologics and why should you care?
Thursday, November 17, 2:30 PM EST

Click here to Register!

Role of biotechnology in medical advancements
What are biologics
Examples of biologic medicines
Manufacturing process
Chemical drugs vs. biologic medicines
Implications of size, variability, complexity
What’s next for biotechnology

Biosimilars 101: What are biosimilars and why should you care?
Thursday, December 1, 2:30 PM EST

Click here to register!

What are biosimilars
Why are biosimilars not generics
Manufacturing
The FDA’s “biosimilar pathway”
Policy Considerations

Pharmacovigilance 101: What is it and why is it important?
Thursday, December 15, 2:30 PM EST

Click here to register!

What is pharmacovigilance
Track & Trace systems for biologic medicines
Coding, Naming, Labeling
Down the Road: Interchangeability and Drug Substitution

Latest News

April 2024 Newsletter

ASBM’s Michael Reilly: Preserve the US Interchangeable Standard that Has Helped Drive Physician and Patient Confidence in Biosimilars In an April interview with EndpointsNews, an FDA official called on Congress to eliminate the distinction between biosimilars (which can be prescribed in place of their reference products by a physician) and “interchangeable” biosimilars, which can be substituted by pharmacists the […]

March 2024 Newsletter

Biden Administration HHS Budget Would Permit Third-Party Substitution of All Biosimilars On March 11th, the Biden Administration released its FY25 HHS Budget. In response, ASBM Executive Director Michael Reilly published a blog post sharing his concerns with the Administration’s proposal to permit widespread automatic (pharmacy-level) substitution of all biosimilars in place of their reference products; without physician approval […]

ASBM’s Michael Reilly: Preserve the US Interchangeable Standard that Has Helped Drive Physician and Patient Confidence in Biosimilars

In an April interview with EndpointsNews, an FDA official called on Congress to eliminate the distinction between biosimilars (which can be prescribed in place of their reference products by a physician) and “interchangeable” biosimilars, which can be substituted by pharmacists the way generics are. Doing so would undermine physician confidence in biosimilars and jeopardize treatment stability for many […]